drug_type
RELEVANT_DRUG
intervention_type
Biological (mRNA vaccine)
drug_description
Personalized therapeutic mRNA cancer vaccine encoding patient-specific tumor neoantigens; administered intradermally to be taken up by antigen-presenting cells, translated and presented via MHC I/II to prime neoantigen-specific CD8+ and CD4+ T cells for tumor cell killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Cancer Vaccines
drug_category
mRNA VACCINE
drug_class
Vaccine
drug_delivery_route
Intradermal
drug_mechanism_of_action
Personalized mRNA encoding patient-specific tumor neoantigens is delivered intradermally, taken up by antigen-presenting cells (e.g., dendritic cells), translated into neoantigen proteins, and processed for presentation on MHC class I and II. This primes and expands neoantigen-specific CD8+ cytotoxic T cells and CD4+ helper T cells, leading to immune-mediated tumor cell killing.
drug_name
iNeo-Vac-R01
nct_id_drug_ref
NCT06026800